Caris Life Sciences and Miraca Holdings Complete Sale of Anatomic Pathology Business
Caris Life Sciences
22.11.2011 17:38
---------------------------------------------------------------------------
TOKYO and IRVING, Texas, 2011-11-22 17:38 CET (GLOBE NEWSWIRE) --
Miraca Holdings Inc. ('Miraca'), Japan's largest clinical diagnostics and
laboratory testing service provider, and Caris Life Sciences, Inc. ('CLS'), a
privately-held company headquartered in Texas specializing in the development
and commercialization of the highest quality anatomic pathology, molecular
profiling, and blood-based diagnostic technologies, today announced that they
have completed the sale of CLS' anatomic pathology ('AP') business to Miraca.
As listed under the terms of the transaction, originally announced on Oct. 6,
2011, Miraca has acquired the AP business operated by Caris Diagnostics, Inc.
('CDx,' a 100% subsidiary of CLS) and its subsidiaries and affiliates. The
total purchase price was $725 million, including the repayment of the existing
debt, subject to customary post-closing price adjustments.
'Both companies are extremely well-positioned for the future, and we are
grateful to Mr. Halbert and his team for their long-term investment in the
world-class AP offerings that we have acquired,' said Dr. Hiromasa Suzuki,
Ph.D., President and CEO of Miraca. 'With the power of Caris' successful,
proven AP business, we will continue to provide the highest-quality diagnostic
services in gastroenterology, dermatology, urology and hematology, and we look
forward to both investing in and building the business going forward.'
CLS and Miraca Holdings have worked together to ensure a seamless transition of
CLS' AP business. Both parties emphasized that the clinician, patient and payor
stakeholders will continue to receive the comprehensive, high-quality
diagnostic services to which they are accustomed.
'Miraca shares our mission of providing superior healthcare through better,
more informed diagnostics, and I know that the patients and physicians we have
served so well over the years will continue to benefit from outstanding
diagnostic services under Miraca's leadership,' said David D. Halbert, Chairman
and CEO of CLS. 'The future is also very bright for Caris Life Sciences, which
will now focus exclusively on the advancement and delivery of the Caris Target
Now evidence-based molecular profiling service and the transformative Carisome(tm)
platform, a proprietary, blood-based testing technology for cancer and other
complex diseases.'
As a result of today's closing, Caris' Target Now and Carisome businesses and
associated legal entities have been transitioned into a new holding company,
Caris Life Sciences, Ltd.
About Miraca Holdings
With group net sales of JPY165.7 billion (FYE 3/2010), Miraca Holdings, a
Japan-based holding company in the healthcare sector, is engaged in the
business consisting of three segments: (i) development, manufacture, and
commercialization of in vitro diagnostics, (ii) clinical laboratory testing,
and (iii) other healthcare related businesses, which are conducted by its
subsidiaries and affiliates including Fujirebio Inc., a leading supplier of in
vitro diagnostics in Japan, and SRL, Inc. ('SRL'), Japan's largest commercial
laboratory. SRL offers comprehensive clinical laboratory testing services to
medical institutes throughout the nation, ranging from general testing to
esoteric testing, including gene-based tests. To learn more, please visit
www.miraca-holdings.co.jp.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on developing and
delivering innovative molecular diagnostic, prognostic and theranostic
services. The company's evidence-based molecular profiling service, Caris
Target Now(tm), matches molecular data generated from a patient's tumor with
biomarker/drug associations derived from the world's leading clinical cancer
literature. Caris Target Now uses the most advanced and clinically-relevant
technologies to provide physicians with information to aid in the selection of
personalized cancer treatments more likely to work for each patient. Caris is
also developing a series of blood tests based on the company's patented
Carisome(tm) platform -- a proprietary, blood-based testing technology for
diagnosis, prognosis and theranosis of cancer and other complex diseases.
Through the precise and personalized information provided by technologies like
Caris Target Now and Carisome, the company believes that the quality of
healthcare can be dramatically improved, while also significantly reducing
costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers
services throughout the United States, Europe and other international markets.
To learn more, please visit www.carislifesciences.com or
www.caristargetnow.com.
CONTACT: Miraca Holdings Inc.
Hiroaki Kimura
General Manager
IR Public Relations Department
20F, STEC Bldg.,1-24-1 Nishishinjuku,
Shinjuku-ku, Tokyo 160-0023, Japan
Tel: +81-3-5909-3337
hk-kimura@miraca-holdings.co.jp
Caris Life Sciences
Holly R. Clark
VP, Corporate Marketing & Communications
6655 North MacArthur Blvd.
Irving, TX 75039
214-596-7060
hclark@carisls.com
News Source: NASDAQ OMX
22.11.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Caris Life Sciences
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901136724
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Caris Life Sciences
22.11.2011 17:38
---------------------------------------------------------------------------
TOKYO and IRVING, Texas, 2011-11-22 17:38 CET (GLOBE NEWSWIRE) --
Miraca Holdings Inc. ('Miraca'), Japan's largest clinical diagnostics and
laboratory testing service provider, and Caris Life Sciences, Inc. ('CLS'), a
privately-held company headquartered in Texas specializing in the development
and commercialization of the highest quality anatomic pathology, molecular
profiling, and blood-based diagnostic technologies, today announced that they
have completed the sale of CLS' anatomic pathology ('AP') business to Miraca.
As listed under the terms of the transaction, originally announced on Oct. 6,
2011, Miraca has acquired the AP business operated by Caris Diagnostics, Inc.
('CDx,' a 100% subsidiary of CLS) and its subsidiaries and affiliates. The
total purchase price was $725 million, including the repayment of the existing
debt, subject to customary post-closing price adjustments.
'Both companies are extremely well-positioned for the future, and we are
grateful to Mr. Halbert and his team for their long-term investment in the
world-class AP offerings that we have acquired,' said Dr. Hiromasa Suzuki,
Ph.D., President and CEO of Miraca. 'With the power of Caris' successful,
proven AP business, we will continue to provide the highest-quality diagnostic
services in gastroenterology, dermatology, urology and hematology, and we look
forward to both investing in and building the business going forward.'
CLS and Miraca Holdings have worked together to ensure a seamless transition of
CLS' AP business. Both parties emphasized that the clinician, patient and payor
stakeholders will continue to receive the comprehensive, high-quality
diagnostic services to which they are accustomed.
'Miraca shares our mission of providing superior healthcare through better,
more informed diagnostics, and I know that the patients and physicians we have
served so well over the years will continue to benefit from outstanding
diagnostic services under Miraca's leadership,' said David D. Halbert, Chairman
and CEO of CLS. 'The future is also very bright for Caris Life Sciences, which
will now focus exclusively on the advancement and delivery of the Caris Target
Now evidence-based molecular profiling service and the transformative Carisome(tm)
platform, a proprietary, blood-based testing technology for cancer and other
complex diseases.'
As a result of today's closing, Caris' Target Now and Carisome businesses and
associated legal entities have been transitioned into a new holding company,
Caris Life Sciences, Ltd.
About Miraca Holdings
With group net sales of JPY165.7 billion (FYE 3/2010), Miraca Holdings, a
Japan-based holding company in the healthcare sector, is engaged in the
business consisting of three segments: (i) development, manufacture, and
commercialization of in vitro diagnostics, (ii) clinical laboratory testing,
and (iii) other healthcare related businesses, which are conducted by its
subsidiaries and affiliates including Fujirebio Inc., a leading supplier of in
vitro diagnostics in Japan, and SRL, Inc. ('SRL'), Japan's largest commercial
laboratory. SRL offers comprehensive clinical laboratory testing services to
medical institutes throughout the nation, ranging from general testing to
esoteric testing, including gene-based tests. To learn more, please visit
www.miraca-holdings.co.jp.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on developing and
delivering innovative molecular diagnostic, prognostic and theranostic
services. The company's evidence-based molecular profiling service, Caris
Target Now(tm), matches molecular data generated from a patient's tumor with
biomarker/drug associations derived from the world's leading clinical cancer
literature. Caris Target Now uses the most advanced and clinically-relevant
technologies to provide physicians with information to aid in the selection of
personalized cancer treatments more likely to work for each patient. Caris is
also developing a series of blood tests based on the company's patented
Carisome(tm) platform -- a proprietary, blood-based testing technology for
diagnosis, prognosis and theranosis of cancer and other complex diseases.
Through the precise and personalized information provided by technologies like
Caris Target Now and Carisome, the company believes that the quality of
healthcare can be dramatically improved, while also significantly reducing
costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers
services throughout the United States, Europe and other international markets.
To learn more, please visit www.carislifesciences.com or
www.caristargetnow.com.
CONTACT: Miraca Holdings Inc.
Hiroaki Kimura
General Manager
IR Public Relations Department
20F, STEC Bldg.,1-24-1 Nishishinjuku,
Shinjuku-ku, Tokyo 160-0023, Japan
Tel: +81-3-5909-3337
hk-kimura@miraca-holdings.co.jp
Caris Life Sciences
Holly R. Clark
VP, Corporate Marketing & Communications
6655 North MacArthur Blvd.
Irving, TX 75039
214-596-7060
hclark@carisls.com
News Source: NASDAQ OMX
22.11.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Caris Life Sciences
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901136724
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------